

## Review Article

# Experimental Strategies of Mesenchymal Stem Cell Propagation: Adverse Events and Potential Risk of Functional Changes

Katarzyna Drela , Luiza Stanaszek , Adam Nowakowski, Zuzanna Kuczynska ,  
and Barbara Lukomska 

NeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

Correspondence should be addressed to Barbara Lukomska; [barbara.lukomska@imdik.pan.pl](mailto:barbara.lukomska@imdik.pan.pl)

Received 22 October 2018; Revised 28 December 2018; Accepted 13 January 2019; Published 6 March 2019

Academic Editor: Katia Mareschi

Copyright © 2019 Katarzyna Drela et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stem cells (MSCs) are attractive candidates for cell-based tissue repair approaches. Hundreds of clinical trials using MSCs have been completed and many others are still being investigated. For most therapeutic applications, MSC propagation *in vitro* is often required. However, *ex vivo* culture condition is not fully physiological and may affect biological properties of MSCs including their regenerative potential. Moreover, both cell cryopreservation and labelling procedure prior to infusion may have the negative impact on their expected effect *in vivo*. The incidence of MSC transformation during *in vitro* culture should be also taken into consideration before using cells in stem cell therapy. In our review, we focused on different aspects of MSC propagation that might influence their regenerative properties of MSC. We also discussed the influence of different factors that might abolish MSC proliferation and differentiation as well as potential impact of stem cell senescence and aging. Despite of many positive therapeutic effects of MSC therapy, one has to be conscious about potential cell changes that could appear during manufacturing of MSCs.

## 1. Introduction

Mesenchymal stem cells (MSCs) are one of the most exploited cell types in regenerative medicine of many clinical applications. Most of scientific reports demonstrate the positive aspects of cell therapy not quoting the adverse events that might influence the quality of the final product. However, it is important to bear in mind that MSC is the heterogeneous cell population with different regenerative properties that may affect the final result of stem cell treatment. Moreover, the crucial fact is the source of MSC isolation and the age of the donor. It is already known that the population of MSCs obtained from older or diseased patients is different in comparison to young and healthy people. Due to the infrequent presence of MSCs within tissues, *in vitro* propagation is almost always required to achieve a sufficient cell number for *in vivo* application. Unfortunately, *in vitro* cell multiplication is not neutral for MSC biological properties. In our review, the potential risks of MSC culture are highlighted including the effects of multiple, frequently nonphysiological

conditions during *in vitro* culture such as oxygen level, cell density, medium content, passage number, and proliferative senescence that altogether may alter MSC condition (Figure 1). Additionally, the influences of cryopreservation methods are discussed. Furthermore, we point out the aspects of MSC labelling that should be applied with caution and consideration of its influence on the labelled cells.

## 2. Diversity of MSCs

The first reports on adult stem cells isolated from bone marrow appeared more than 50 years ago. At the beginning, the scientists proposed the term mesenchymal stem cells (MSCs), initially referred to multilineage progenitor cells showing three lineage differentiation abilities. It has been demonstrated that MSCs are heterogeneous cells with several populations significantly varying in regenerative potentials. Recent findings confirmed that these cells comprise only part of the stromal cell population [1, 2]. Subsequently, in nomenclature, the definition “mesenchymal stromal cells”




FIGURE 1: Scheme of potential risks of adverse events during MSC *in vitro* culture.

was proposed for MSCs as that name would reflect the stromal origin of the cells [1]. Lately, Caplan and other researchers proposed for MSCs the term “medical signaling cells” [3]. They suggested that MSC multipotency is not a pivotal aspect of cell therapy and thus primarily referred to their paracrine function as a major activity in tissue repair [4]. It needs to be underlined that regarding diverse MSC tissue origin and/or donors, secretome of the cells might differ [5]. Moreover, recent research demonstrated that MSCs isolated from diseased patients might release factors that might negatively influence regenerative processes [6]. Furthermore, there are some controversies regarding MSC ontogeny. Some researchers suggest that MSCs are present in almost all tissues, being located in perivascular niches, which suggests their close relation to pericytes [7, 8]. Such controversial view on MSC origin was demonstrated by Takashima and colleagues suggesting that the first population of MSCs during development is derived from the neuroectodermal neural crest cells [9]. Further investigation by Coste’s group proved that the bone marrow contains population of cells with neural crest features which are able to differentiate into neurons and Schwann cells [10]. The neuroectodermal origin could explain the neural differentiation potential of MSCs documented in many recent papers [11].

Clinical applications of MSCs have been tested for many years. So far, bone marrow-derived MSCs are the most often used type of cells in more than 50% of clinical trials [12]. Since the aspiration of bone marrow tissue is a traumatic and painful procedure, the researchers quest for an alternative source for MSCs. Recently, MSC population have been isolated from the tissues that are discarded such as umbilical cord, placenta, or fat tissue obtained from liposuction procedures. It has been shown that neonatal tissues have biological advantages in comparison to adult sources that make them a useful source for stem cells including MSCs. Neonatal tissues are easily available, which avoid invasive technical procedures and they are ethically noncontroversial. It was shown that MSCs derived from neonatal tissues have higher biological capacities than MSCs obtained from adult sources. Several studies showed better proliferative capacity, long lifespan, and efficient differentiation potential of MSCs from birth-associated tissues over BM-MSCs [13, 14]. Moreover, neonatal tissues may contain embryonic or premature cells

including the cells at earlier stage of development [15]. Nowadays, it is still unclear, which tissue source is optimal to obtain MSCs for clinical transplantation. Unanswered question is whether MSCs obtained from the different sources are still the same cells or represent a different population. These subsets of cells can be isolated from the different niches, each with distinct potential for therapeutic applications.

### 3. Potential Risks during MSC Expansion *In Vitro* Affecting Therapeutic Properties

**3.1. MSC Culture *In Vitro*.** Although hMSCs are present in almost all tissues, their frequency is relatively low [2]. Most of clinical protocols recommend  $20\text{--}100 \times 10^6$  hMSCs per treatment; therefore, in order to obtain such a high number of cells, hMSCs have to be expanded *in vitro* for at least 4–8 weeks before transplantation. To achieve positive results in clinical application, it is important to get high number of therapeutic cells. MSC isolation protocols rely on the ability of these cells to adhere to the plastic surface; however, this method leads to a heterogeneous population of stem cells with a substantial population of progenitor cells and also other cell types [16]. The other method is the isolation of MSCs using mechanical explant approach or proteolytic enzyme treatment with collagenase, which may impact on biological properties of the isolated cells [17–19]. Moreover, the expansion of MSCs using traditional plastic adherence cell culture in media supplemented with serum and continuous exposure to oxygen could result in the decrease of proliferative and differentiation potential with each subsequent passage. It is recently reported that oxygen level is a crucial factor in stem cell biology. Physiologically, MSCs are settled in hypoxic niches where oxygen concentration ranges between 2 and 7% [20]. Therefore, in many recent studies, hypoxic culture condition is tested in terms of MSC functions. In most experiments, MSC proliferation rate was increased in hypoxic conditions (5%) compared to standard atmospheric (21%) oxygen level culture [21]. Moreover, *in vitro* culture of hMSCs in low concentration of oxygen significantly increased cell lifespan, limited oxidative stress, DNA damage, telomere shortening, and chromosomal aberrations. At the same time, MSCs expanded in 5% oxygen level presented HIF-1 $\alpha$  expression leading to improvement of

several MSC functions influencing on their therapeutic potential while maintaining stable karyotype. In addition, hypoxia preconditioning was reported to increase the angiogenic properties of MSCs [22–25]. Unfortunately, the expansion of human stem cells *in vitro* before their transplantation is usually performed at 20% O<sub>2</sub>. The results obtained by Estrada and coworkers suggest that cell culture at low oxygen tension favoured the metabolic state of MSCs, increased glycolysis, and diminished oxidative phosphorylation [26]. Culturing MSCs at 20% O<sub>2</sub> changed their metabolism and significantly increased level of oxidative stress. Moreover, the group of Vertelov and colleagues demonstrated that hypoxic conditions influenced on MSC motility toward the injury site [27]. Recent data underlines the importance of culturing of MSCs in hypoxic condition that might increase regenerative potential of the cells such as self-renewing capacity and immunomodulatory properties [28]. Therefore, it is crucial that stem cells designated for human application should be expanded in low oxygen condition to augment their biologic potential.

Even though transplantation of MSCs has emerged as an effective method to treat diseased or damaged tissues, the most of MSCs used for clinical trials are prepared in different laboratories with often insufficient manufacturing quality control. In particular, many laboratories do not have standardized procedures for *in vitro* isolation of MSCs from different tissue samples, resulting in heterogeneous population of cells, which lead to unreproducible experimental and clinical results. Criteria defined by ISCT guidelines for MSC characterization are not enough to identify MSCs and could be addressed for many other cell types [29]. This fact causes a lot of discrepancies in the establishment of the real nature of MSCs and their impact on tissue repair.

Another aspect that should be considered is the influence of culture reagents, i.e., proteolytic enzymes to detach cells, culture media, and storage reagents on biological properties of expanded MSCs [30]. The addition of fetal bovine serum commonly used in culture media is questionable, since the components and growth factors present in the serum are not well characterized. The ideal culture media for MSC expansion *ex vivo* should contain standard defined nutrients accordingly to the cell type. Moreover, proteolytic enzymes used for cell passaging or tissue digestion could promote extracellular matrix (ECM) protein damage and thus may modify activation of variety of intracellular signaling pathways [31]. In most cases, expanded MSCs have to be stored frozen until the time of treatment and the storage condition could alter the quality of the product. Some preclinical reports demonstrating that cryopreservation does not affect biological properties of MSCs, i.e., marker expression, proliferation rate, or differentiation potential [32]. However, the other studies have shown that cryopreservation could exert many adverse events and alter MSC phenotypes and cell function. The optimal freezing and thawing temperature control, cryopreservation media, and long-term storage in liquid nitrogen are the main key factors that should be considered. Recently, the new strategies and cryoprotective agents, e.g., polyvinylpyrrolidone PVP, methylcellulose, and trehalose for MSC storage, have been demonstrated [33, 34].

However, the freezing media consisting DMSO, despite of its toxicity for many types of cells, are still the most frequently used cryopreserving solution. Adverse effects of DMSO were reported both in animals and humans [35, 36]. Because of the toxic effect of DMSO, it is recommended to remove it from the thawed cells before transplantation usually using the washing steps in isotonic solutions. There are reports showing that after the infusion of MSCs previously frozen in DMSO, the patients developed transient complications including headache, vomiting, and hyper or hypotension; some of them presented respiratory and cardiovascular problems [37]. Hydroxyethyl starch (HES) commonly used for freezing different cell types could be another alternative for DMSO in cell cryoprotection [38]. Nevertheless, up to now, it was not tested in protocols for MSC cryopreservation.

**3.2. Impaired Proliferation of MSCs.** MSCs cultured *in vitro* have usually high proliferation properties; however, cell proliferation rate depends on many factors, i.e., source of MSCs, the stage of cells, or culture condition. It has been shown that neonatal MSCs have higher proliferation potential in comparison to MSCs derived from adult sources [13]. However, nonoptimal culture condition could alter MSC proliferation. Cell seeding density may have the impact on MSC growth. The initial cell number of mononuclear cells from the whole fraction of the bone marrow is a key factor to obtain efficient population of pure MSCs. Mareschi and coworkers evaluated influence of initial cell density and the time of culture on morphology, metabolic activity, and differentiation potential of BM-MSCs [39]. They have found that the optimal cell growth occurs at a lower initial culture density. MSC culture derived from initial high cell plating densities results in increased number of flat cells and low proliferation rate. However, there is a limit of low cell culture density and the samples plated at 10–100 cells/cm<sup>2</sup> did not expand effectively. The recent data revealed that the best results for clinical application were obtained when the whole BM-MSC population were expanded at the density of 10.000/cm<sup>2</sup> [39].

Current observations suggest that MSC expansion in three-dimensional (3D) structures could increase their therapeutic potential when compared to traditional two-dimensional (2D) culture [40]. Different culture methods have been employed to obtain efficient 3D spheroids of MSCs. Recently, an efficient method to produce MSC aggregates was proposed by Bogdanova et al. MSCs derived from adipose tissue (AT-MSCs) cultured *in vitro* in a special condition spontaneously formed aggregate-3D bodies and expressed pluripotent markers including Nanog and Oct3/4 [41]. The authors suggest that in 3D culture, MSCs retain their natural features of stem cells. However, cell aggregates can reach a big size and the injection of a pool of such condensed cells into the tissue may have detrimental effect. The biomass aggregates could end with pulmonary embolism or infarctions after systemic delivery. Moreover, not all cells in 3D bodies are at the same differentiation stage [42].

In terms of clinical transplantation, it is important to culture MSCs in media depriving of animal components, i.e., bovine products that have a potential risk of viral transmission or prion diseases as well as immune system activation

of graft recipients. Autologous or allogeneic-derived plasma or platelet lysates represent more safe substitutes than FBS and allow efficient proliferation of MSCs [43, 44]. Nevertheless, some of the reports indicate the possibility of using commercially available xeno-free media for MSC culture [45, 46]. Recent reports demonstrated that the use of human platelet lysates (hPL) results in enhanced proliferation without changing morphology and function of MSCs [39]. Smith and coworkers optimized GMP expansion protocol for umbilical cord-derived MSCs (UC-MSCs) supplemented with different concentration of hPL. They observed that MSCs cultured in media enriched with 10% of platelet-rich plasma (PRP) have the most efficient proliferation rate [47]. Similar results confirming efficacy of using platelet lysates have been demonstrated in BM-MSC culture [43]. However, it was shown that autologous plasma obtained from elderly patients diminished MSC proliferation properties [48, 49].

**3.3. Unsettled Differentiation of MSCs.** There are some other risk factors which should be taken into consideration before clinical transfer of MSCs. Among them, one factor is the incorrect differentiation ability of MSCs. According to ISCT minimal criteria, MSCs should differentiate into three mesodermal lineages including adipocytes, osteocytes, and chondrocytes [1]. However, the results obtained from *in vitro* studies suggested the possibility of MSC differentiation into ectodermal and endodermal cells [50]. Indeed, numerous differentiation protocols have described the ability of MSCs to turn into other cell types. Recent published data demonstrated that cell senescence associated with aging is the main factor that abolished multilineage potential of MSCs [51, 52]. Furthermore, some reports indicated the data concerning spontaneous differentiation of MSCs into unwitting cell types after transplantation. Recently, it was demonstrated that transplantation of BM-MSCs into heart in mouse experimental model of cardiomyopathy led to calcification. [53]. It has been suggested that MSC differentiation is strictly regulated by specific paracrine mediators. Osteoblastic differentiation of MSCs is stimulated by epidermal growth factor (EGF), which enhances BMP9-induced early and late osteogenic markers of MSCs cultured *in vitro*. The cross talk between BMP and EGF could be beneficial to induce osteogenesis in bone repair [54]. In contrary, bone marrow-derived MSCs treated with transforming growth factor  $3\beta$  (TGF  $\beta$ ) significantly reduced alkaline phosphate activity and decreased mineral depositions [55]. The other important factor influencing MSC differentiation is the level of oxygen. It has been proven that hypoxia could block MSC osteogenic differentiation by activating the Notch pathway [56]. In contrast, MSC exposure to atmospheric oxygen develops oxygen-stress response and inhibits cell differentiation [22]. The differentiation potential of MSCs observed *in vitro* depends on the presence of cell composition in bone marrow stroma. Abdallah and Kassem demonstrated that adipocytes present in the bone marrow niche could exert inhibitory effect on MSC differentiation properties. Adipocytes could secrete factors that block BMP pathway towards osteoblast lineage [57]. This may have a significant adverse effect in primary cell culture containing different cell populations. The problem of

unwanted differentiation of MSCs was also confirmed in *in vivo* studies in animal models of liver injury and cardiac infarction [58]. Recent data demonstrated the role of micro-environmental factors in heterotopic ossification (HO); therefore, cell therapies in orthopaedic disorders should be considered in terms of potential risks [59]. Breitbach et al. observed the phenomenon of calcification and/or ossification in murine heart tissue when unfractionated bone marrow cells or BM-MSCs were injected into the border zone of heart infarcted area after acute myocardial insult. It suggests the osteogenic differentiation of transplanted cells [53]. The authors did not provide possible rationale for unexpected MSC misdifferentiation in heart tissue. Such phenomenon has not been reported before, but it supposed to warn the scientific community that ossification process may happen following MSC injection in other than bone tissues. The calcification has been also observed by Liao and colleagues in the site of injured abdominal aorta after BM-MSC transplantation in hyperlipidemic rats [60].

The knowledge coming from experimental cardiovascular studies indicating some possible risks of MSC application may suggest that “priming” or “predifferentiation” of bone marrow cells including MSCs may be an optimal approach prior to their transplantation, enhancing their differentiation capacity into cardiomyocytes and limiting misdifferentiation of transplanted cells in the heart niche. The problem of MSC unsettled differentiation may be dissected into two different negative aspects. On one hand, there is the problem of MSC uncontrolled differentiation into unwanted lineages, and on the other, the total loss of differentiation potential at all. This problem may be caused by unspecified culture condition and due to the fact that general population of multipotent MSCs may differ depending of stem cell niche.

#### **4. Aging and Senescence of MSCs and Potential Risk of Transformation**

Mesenchymal stem cells, similarly to other types of cells, undergo senescence after definite number of cell passages *in vitro*. Many papers have demonstrated that long-term expansion of MSCs could induce cellular senescence that is associated with growth arrest and cell apoptosis as well as with a reduction of their “medical” properties [51]. However, the exact mechanism of MSC senescence and molecular signaling pathways still remain unknown. Ko and coworkers have shown that similarly to primary tissue cells, umbilical cord blood-derived MSCs (UCB-MSCs) initiate permanent arrest of cell division after 50 population doublings (PDs), but the process of MSC senescence depends mainly on the source of MSCs [61]. The data published by Stab’s group revealed that AT-MSCs developed a senescent phenotype at seventh population doubling, characterized by significant change in cell morphology with an increase in  $\beta$ -galactosidase expression [62]. The changes associated with senescence are characterized by heterogeneity of cells expressing different phenotypic markers. Previous studies established that MSC aging correlates with the decline of their functions. This process is characterized by phenotype alteration observed in culture including changes in morphology, reduction of

telomere length, and decrease in immunological properties of MSCs [63–65]. Thus, an understanding of the molecular mechanisms controlling MSC senescence is very important to determine age-associated MSC alterations. Furthermore, this knowledge is fundamental for the development of therapeutic intervention that can slow down or reverse age-related degenerative changes and improve repair processes [66]. Bellotti's group indicated that besides  $\beta$ -galactosidase, prelamin A level is a useful marker for detection of senescent MSCs. They confirmed that this nuclear protein level provided an easy and reliable tool to screen MSCs before their use in clinical application [67]. Presently, most of the researchers put special emphasis to the role of oxidative stress to elucidate the mechanism of cellular aging. Recent results published by Estrada and coworkers demonstrated that reactive oxygen species (ROS) level increased cellular stress and accumulation of aberrations associated with cellular senescence [26]. Additionally, it was proved that all *ex vivo* cell expansion procedures favour senescence progression through the accumulation of aneuploid cells [64]. While some authors found that improper expansion could induce premature senescence of MSCs, others demonstrated that MSCs cultured on poly-L-lysine-coated plates could reverse the replicative senescence. Poly-L-lysine surface provides favourable micro-environment where MSCs exhibit higher grow rate and upregulate stemness markers. This method could significantly contribute to the effective preparation of MSCs for cellular therapy [68]. There are reports defining a direct correlation between telomerase (which blocks cell senescence) activity and stem cell function. Hisamatsu and coworkers identified that growth differentiation factor 6 secreted from young MSCs could exert positive effect *in vivo* on aging-associated changes [48]. Age-related changes in MSCs activate senescence-associated secretory phenotype (SASP) and elicit high production of proinflammatory cytokines (IL-1, IL-6, and IL-8) that could abolish the regenerative process [69, 70]. On top of that, in some cases, it has been documented that SASP could promote tumour growth. Senescent MSCs secrete high amount of numerous proteins in comparison to nonsenescent cells. Among factors that reached the highest levels of secretions was LEPTIN, transforming growth factor alpha (TGF $\alpha$ ), IL-8, interferon gamma (IFN-gamma), VCAM1, interferon beta (IFN- $\beta$ ), IL-4, and monocyte chemoattractant protein-1 (MCP-1) [71]. There are reports that demonstrated the effect of MSC aging on their migratory ability, differentiation potential, immunomodulation ability, and tumour progression. Recently, Sepúlveda and coworkers showed how the state of cell senescence affects immunoregulatory activity of hMSCs *in vitro* and *in vivo* [72]. Results published by Di and coworkers indicated that senescent UCB-MSC secrete factors that promote migration and proliferation of breast cancer cells. The authors proved that aged MSCs develop characteristic SASP and produced high level of IL-6, which may be a key factor in tumour progression [70].

Multiple advanced methods are now available to establish chromosomal stability of MSCs including FISH (fluorescence in situ hybridization), spectral karyotyping, and comparative genomic hybridization (CGH) [73]. Previous reports demonstrated that conventional karyotyping is not the most

effective method for evaluation of genomic stability of MSCs for clinical applications. More attentions should be focused on MSC safety based on traditional Giemsa G-banding combined with FISH [74]. Wang and coworkers compared hMSCs obtained from umbilical cord at senescent stage vs early passage using high-resolution array-based comparative genomic hybridization (aCGH). The group analysed different aspects including telomerase activity and telomere length as well as multipotency of MSCs and their surface markers. The authors also distinguished differences in gene expression profile and genomic stability of investigated cells from an early to a late passage [75]. Thus, the chromosomal stability should be routinely tested in expanded MSCs prior their transplantation *in vivo*.

The issue concerning MSC transformation is controversial. There are reports indicated that MSCs cultured *in vitro* undergo malignant transformation [74, 76, 77]. High rate of aneuploidy was demonstrated in rodent MSCs [78]. In terms of human MSCs, it is not clear whether aneuploidy clones observed *in vitro* represent the senescent or transformed cell population [74]. Moreover, many of publications concerning hMSCs transformation were retracted with regard to possibility of contamination of tumour cell lines due to the use of not reliable verification methods.

The other potential risk of MSC therapy in rodents was reported as possible teratogenic capacity that may not be detected during *in vitro* cell culture but may occur *in vivo* following MSC transplantation [76, 77]. Importantly, such adverse effects as *in vivo* sarcoma formation have been reported for rodent MSCs expanded in prolonged *ex vivo* culture, which may potentially lead to accumulation of random mutations occurring in highly proliferating cells. Miura and coworkers have shown that murine BM-MSCs, after many passages in culture, gained unlimited cell proliferation potential and underwent malignant transformation resulting in fibrosarcoma formation observed in multiple organs after intravenous administration of cells [76]. Such transformed MSCs generated in long-term culture exhibited accumulated chromosomal abnormalities, increased telomerase activity, and c-myc expression as well as more efficient resistance to anticancer agents [76]. Recently, Jeong and coworkers demonstrated for the first time that malignant transformation of MSCs may happen not only in prolonged culture but also during short-term *in vitro* expansion [77]. The authors provided evidence that murine BM-MSCs harvested at early passages (P3-P6) and injected directly into peri-infarct area of the injured heart or into hind limb muscles of mice with diabetic neuropathy led to tumour formation in 30% and 46% of treated animals, respectively [77]. Genetic analysis of MSC line used in this study revealed accumulative chromosomal abnormalities including fusion, fragmentation, and ring formation. Importantly, these MSCs demonstrated normal features, i.e., morphology or antigenic profile when cultured *in vitro* (at P4) but their abnormal behaviour was proven exclusively after transplantation [77]. Considering the fact that short expansion period (typically 3–5 passages) is a widely used procedure for hMSC propagation prior to transplantation, the fact of possible cell transformation in such early stages of culture should be considered and MSC

specimens should be always subjected for detailed karyotype analysis. There are some studies providing the evidence that hMSCs may undergo genetic changes and mutate after prolonged cell culture *in vitro* [79, 80]. Such important findings confirm the commonly known rationale for maximally reduced and limited *ex vivo* cell manipulation and culture for any cell type including MSCs, especially when the cells are considered as transplant material in humans. Genomic stability plays a critical role in stem cell-based therapies, and thus, it has emerged much attention. Previous reports demonstrated that embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) frequently develop chromosomal abnormalities or DNA copy number variations (CNVs) during cell propagation [81]. However, human MSCs are stem cells in an intermediate state of differentiation between ESCs and adult cells and it is not fully clear whether MSCs can experience adaptive genetic changes during long-term expansion *in vitro*. It needs to be underlined that the most lately appeared studies concerning transformation of MSCs were performed on animal cells, and up to now, abnormalities of human MSCs were not directly proven. Our unpublished results indicate that human MSCs during long-term culture may alter their phenotype into abnormal cells with improper karyotype. Recently, results published by Stultz's group demonstrated that chromosomal aberrations could be clonally propagated throughout long culture-expanded MSCs [82]. Moreover, a variety of studies demonstrated that aneuploidy could be found not only at the late cell passages but also at early passages of *in vitro* culture of human MSCs derived from the bone marrow or adipose tissue [26, 75, 82].

## 5. Labelling Procedure of MSCs May Influence Their Function

An important issue for future clinical applications employing exogenous MSCs is the knowledge of the fate of the transplanted cells in recipient tissues. For this reason, cell labelling facilitates the determination of the degree of engrafted cells in places of expected actions. Proper cell staining enables the study of the migration routes of exogenous cells and their persistence in the recipient organism and allows the visualization of cell differentiation and monitoring the integration process of transplanted cells with the host tissues or the evaluation of elimination process.

Unfortunately, the methods used for exogenous cells labelling are not indifferent to these cells [83]. Obviously, there is a lot of literature reports on the safety of cell labelling methods proving that labelling of cells have no negative impact on their metabolism, the presence of characteristic surface markers, the differentiation potential, or their immunomodulating properties [84–86]. Small particles of iron oxide (SPIO) labelling MSCs might compromise several aspects of cell biology, i.e., migration properties and colony-forming abilities [87]. Functional tests can be used, in which research on the influence of SPIO on MSCs *in vitro* included the use of an external electromagnetic field could be accomplished. Interestingly, the authors stated that in the absence of an external electromagnetic field, the cell biology

of the labelled MSCs was not compromised. However, in the presence of the magnetic field, the ability of cell colony formation was significantly affected in SPIO-labelled MSCs. Nevertheless, this effect was transient and after magnetic field cessation, the capacity of cells to form colonies returned to preexperiment values [88]. Besides, the expression of several external membrane markers was changed, as well as differentiation into the adipogenic type was improved. In a different study, iron oxide and protamine sulfate (Fe-Pro) aggregates were reported to cause changes in the expression patterns of several markers of MSCs, i.e., transient increase of MSC marker CD146 and undifferentiating status related gene Oct-4 [89]. In the case of SPIOs, it has been shown that the utilization of this contrast agent could be harmful to MSCs depending on the concentration used. In one study, 25  $\mu\text{g}$  Fe/mL of fluorescent SPIO labelling was found to be safe and did not affect cell proliferation rate and cytoskeletal structures; however, osteogenic differentiation potential was declined [90]. Roeder and coworkers showed that elevated doses of SPIO contribute to the disturbances in chondrogenic MSC differentiation; in particular, the cartilage differentiation was distorted, where specific genes were downregulated along with the increasing dose of SPIO [91]. At highest doses tested, moderate cytotoxicity was demonstrated and no significant negative effects were observed on cell viability or mitochondrial activity. To add with, chondrogenesis was disturbed when MSCs were labelled with fluorescent quantum dots. In this case, chondrocyte specific markers evaluated at mRNA and protein level were significantly downregulated [92]. Besides chondrogenesis, osteogenic differentiation was reported to be affected by SPIO labelling. Gold nanoparticles (Au-NPs) similar to iron containing compounds elicit negative effects on MSCs. Nold and coworkers disclosed that Au-NPs caused concentration-correlated depletion of proliferation and were toxic at high doses [93].

In the field of fluorescent labelling, there are some more examples of the negative influence of this kind of cell tagging on MSC biology. Gallina and coworkers reported that after fluorescent silica nanoparticle (SiO<sub>2</sub>-NP) MSC labelling, nanoparticles were accumulated in lysosomes and their number was substantially elevated compared to unlabelled cells [94]. Despite high number of lysosomes, neither oxidative stress nor cytotoxicity was noted. Viral transduction with fluorescent protein encoding genes might compromise MSC natural abilities as well. Ji and coworkers reported that MSCs with transduced expression of GFP had lower colony-forming efficiency and unsettled proliferation rate [95]. In other study, in GFP bearing MSCs, the MMP-2 gene expression was increased which suggests the modification of migration ability showed by GFP bearing MSCs [96]. The other types of fluorescent dyes, i.e., fluorescent lipophilic cationic indocarbocyanine dye (DiI) or bromodeoxyuridine (BrdU), apparently lead to the decreased cell viability. The effect of DiI has been found transient but BrdU caused steady decrease of cell viability during the whole cultivation period [97]. On the other hand, fluorescent dye DiD was found to disturb chondrogenesis of DiD-labelled MSCs, where glycosaminoglycan production was heavily diminished [98]. Finally, there are some data reporting that firefly luciferase

gene transduction in MSCs caused exclusive diminution in adipogenic differentiation with unaltered chondrogenic and osteogenic differentiation [99].

There is also some evidence that radioactive labelling discomposes MSC proliferation rate. Fludeoxyglucose-18F- (<sup>18</sup>F-FDG-) treated MSCs proliferated slower shortly after <sup>18</sup>F-FDG administration, followed by an increase in proliferation, to finally return to the proliferation rate same as untreated cells [100].

## 6. Conclusions

In the last few years, considerable progress has been made in terms of MSC transplantation as the therapeutic approach for different diseases. However, one has to be aware that despite of great potential for application in therapeutic approach, MSCs demonstrate a number of limitations. In this review, we intended to emphasize the potential problems and obstacles associated with MSC therapies observed by various investigators including the risk related with manufacturing procedures and with biological properties of the cells. The bothering issue is that the protocols for isolation and expansion of MSCs vary widely between laboratories, which may significantly influence the effectiveness of stem cell therapy. Therefore, it is crucial to develop international standards of MSC manufactures, which should be processed in good medical practice (GMP) grade, cost-effective, clinically practical, and based on facts. Only then, stem cell therapy will become an established and widely adopted treatment. It is also important to define safety of stem cells therapy and determine therapeutic windows in long-term follow-up, as well as monitoring patients for long time in terms of potential risk of tumour transformations. Up to now, it is difficult to conclude about significant beneficial effects of MSC therapy in different diseases due to the still primary stage of research within this field and the variability within the procedures used in different laboratories. Although the results coming from dozens of clinical trials employing MSCs are encouraging, the common clinical use of MSCs is still under development and is not a routine procedure.

## Conflicts of Interest

The authors report no conflicts of interest in this work.

## Authors' Contributions

All authors read and approved the final version of the manuscript.

## Acknowledgments

This work was supported by NCR&D grant STRATEG-MED1/235773/19/NCBR/2016 "EXPLORE ME."

## References

- [1] M. Dominici, K. le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," *Cytotherapy*, vol. 8, no. 4, pp. 315–317, 2006.
- [2] A. I. Caplan, "Why are MSCs therapeutic? New data: new insight," *The Journal of Pathology*, vol. 217, no. 2, pp. 318–324, 2009.
- [3] A. I. Caplan, "Mesenchymal stem cells: time to change the name!," *Stem Cells Translational Medicine*, vol. 6, no. 6, pp. 1445–1451, 2017.
- [4] A. I. Caplan, "Adult mesenchymal stem cells: when, where, and how," *Stem Cells International*, vol. 2015, Article ID 628767, 6 pages, 2015.
- [5] N. Kalinina, D. Kharlampieva, M. Loguinova et al., "Characterization of secretomes provides evidence for adipose-derived mesenchymal stromal cells subtypes," *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 221, 2015.
- [6] N. A. Dzhoiyashvili, A. Y. Efimenko, T. N. Kochegura et al., "Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2," *Journal of Translational Medicine*, vol. 12, no. 1, p. 337, 2014.
- [7] L. E. B. de Souza, T. M. Malta, S. Kashima Haddad, and D. T. Covas, "Mesenchymal stem cells and pericytes: to what extent are they related?," *Stem Cells and Development*, vol. 25, no. 24, pp. 1843–1852, 2016.
- [8] A. I. Caplan, "New MSC: MSCs as pericytes are sentinels and gatekeepers," *Journal of Orthopaedic Research*, vol. 35, no. 6, pp. 1151–1159, 2017.
- [9] Y. Takashima, T. Era, K. Nakao et al., "Neuroepithelial cells supply an initial transient wave of MSC differentiation," *Cell*, vol. 129, no. 7, pp. 1377–1388, 2007.
- [10] C. Coste, V. Neirinckx, A. Sharma et al., "Human bone marrow harbors cells with neural crest-associated characteristics like human adipose and dermis tissues," *PLoS One*, vol. 12, no. 7, article e0177962, 2017.
- [11] Y. S. Takeda and Q. Xu, "Neuronal differentiation of human mesenchymal stem cells using exosomes derived from differentiating neuronal cells," *PLoS One*, vol. 10, no. 8, article e0135111, 2015.
- [12] T. Squillaro, G. Peluso, and U. Galderisi, "Clinical trials with mesenchymal stem cells: an update," *Cell Transplantation*, vol. 25, no. 5, pp. 829–848, 2016.
- [13] R. Donders, J. F. J. Bogie, S. Ravanidis et al., "Human Wharton's jelly-derived stem cells display a distinct immunomodulatory and progenerative transcriptional signature compared to bone marrow-derived stem cells," *Stem Cells and Development*, vol. 27, no. 2, pp. 65–84, 2018.
- [14] N. Beeravolu, C. McKee, A. Alamri et al., "Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta," *Journal of Visualized Experiments*, no. 122, article e55224, 2017.
- [15] I. Arutyunyan, A. Elchaninov, A. Makarov, and T. Fatkhudinov, "Umbilical cord as prospective source for mesenchymal stem cell-based therapy," *Stem Cells International*, vol. 2016, Article ID 6901286, 17 pages, 2016.
- [16] H. Busser, M. Najjar, G. Raicevic et al., "Isolation and characterization of human mesenchymal stromal cell subpopulations: comparison of bone marrow and adipose tissue," *Stem Cells and Development*, vol. 24, no. 18, pp. 2142–2157, 2015.
- [17] F. Hendijani, H. Sadeghi-Aliabadi, and S. Haghjooy Javanmard, "Comparison of human mesenchymal stem

- cells isolated by explant culture method from entire umbilical cord and Wharton's jelly matrix," *Cell and Tissue Banking*, vol. 15, no. 4, pp. 555–565, 2014.
- [18] C. Capelli, O. Pedrini, R. Valgardsdottir, F. Da Roit, J. Golay, and M. Introna, "Clinical grade expansion of MSCs," *Immunology Letters*, vol. 168, no. 2, pp. 222–227, 2015.
- [19] P. van Pham, N. C. Truong, P. T.-B. le et al., "Isolation and proliferation of umbilical cord tissue derived mesenchymal stem cells for clinical applications," *Cell and Tissue Banking*, vol. 17, no. 2, pp. 289–302, 2016.
- [20] A. Dalloul, "Hypoxia and visualization of the stem cell niche," *Methods in Molecular Biology*, vol. 1035, pp. 199–205, 2013.
- [21] C. Zhu, J. Yu, Q. Pan et al., "Hypoxia-inducible factor-2 alpha promotes the proliferation of human placenta-derived mesenchymal stem cells through the MAPK/ERK signaling pathway," *Scientific Reports*, vol. 6, no. 1, article 35489, 2016.
- [22] S. V. Boregowda, V. Krishnappa, J. W. Chambers et al., "Atmospheric oxygen inhibits growth and differentiation of marrow-derived mouse mesenchymal stem cells via a p53-dependent mechanism: implications for long-term culture expansion," *Stem Cells*, vol. 30, no. 5, pp. 975–987, 2012.
- [23] A. M. Bader, K. Klose, K. Bieback et al., "Hypoxic preconditioning increases survival and pro-angiogenic capacity of human cord blood mesenchymal stromal cells in vitro," *PLoS One*, vol. 10, no. 9, article e0138477, 2015.
- [24] M. Ciria, N. A. García, I. Ontoria-Oviedo et al., "Mesenchymal stem cell migration and proliferation are mediated by hypoxia-inducible factor-1 $\alpha$  upstream of notch and SUMO pathways," *Stem Cells and Development*, vol. 26, no. 13, pp. 973–985, 2017.
- [25] B. Lv, F. Li, J. Fang et al., "Hypoxia inducible factor 1 $\alpha$  promotes survival of mesenchymal stem cells under hypoxia," *American Journal of Translational Research*, vol. 9, no. 3, pp. 1521–1529, 2017.
- [26] J. C. Estrada, C. Albo, A. Benguría et al., "Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis," *Cell Death and Differentiation*, vol. 19, no. 5, pp. 743–755, 2012.
- [27] G. Vertelov, L. Kharazi, M. G. Muralidhar, G. Sanati, T. Tankovich, and A. Kharazi, "High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA," *Stem Cell Research & Therapy*, vol. 4, no. 1, pp. 5–5, 2013.
- [28] B. Antebi, L. A. Rodriguez, K. P. Walker et al., "Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells," *Stem Cell Research & Therapy*, vol. 9, no. 1, p. 265, 2018.
- [29] M. Maleki, F. Ghanbarvand, M. R. Behvarz, M. Ejtemaei, and E. Ghadirkhomi, "Comparison of mesenchymal stem cell markers in multiple human adult stem cells," *International Journal of Stem Cells*, vol. 7, no. 2, pp. 118–126, 2014.
- [30] C. Adamzyk, T. Emonds, J. Falkenstein et al., "Different culture media affect proliferation, surface epitope expression, and differentiation of ovine MSC," *Stem Cells International*, vol. 2013, Article ID 387324, 13 pages, 2013.
- [31] V. Penna, M. V. N. Lipay, M. T. Duailibi, and S. E. Duailibi, "The likely role of proteolytic enzymes in unwanted differentiation of stem cells in culture," *Future Science OA*, vol. 1, no. 3, 2015.
- [32] M. Haack-Sørensen, A. Ekblond, and J. Kastrup, "Cryopreservation and revival of human mesenchymal stromal cells," *Methods in Molecular Biology*, vol. 1416, pp. 357–374, 2016.
- [33] B. Larijani, H. Aghayan, P. Goodarzi et al., "Clinical grade human adipose tissue-derived mesenchymal stem cell banking," *Acta Medica Iranica*, vol. 53, no. 9, pp. 540–546, 2015.
- [34] C. Lechanteur, A. Briquet, O. Giet, O. Delloye, E. Baudoux, and Y. Beguin, "Clinical-scale expansion of mesenchymal stromal cells: a large banking experience," *Journal of Translational Medicine*, vol. 14, no. 1, p. 145, 2016.
- [35] S. B. Shivakumar, D. Bharti, R. B. Subbarao et al., "DMSO- and serum-free cryopreservation of Wharton's jelly tissue isolated from human umbilical cord," *Journal of Cellular Biochemistry*, vol. 117, no. 10, pp. 2397–2412, 2016.
- [36] M. Espina, H. Jülke, W. Brehm, I. Ribitsch, K. Winter, and U. Delling, "Evaluation of transport conditions for autologous bone marrow-derived mesenchymal stromal cells for therapeutic application in horses," *PeerJ*, vol. 4, article e1773, 2016.
- [37] C. Morris, L. de Wreede, M. Scholten et al., "Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide," *Transfusion*, vol. 54, no. 10, pp. 2514–2522, 2014.
- [38] T. K. Chatzistamatiou, A. C. Papassavas, E. Michalopoulos et al., "Optimizing isolation culture and freezing methods to preserve Wharton's jelly's mesenchymal stem cell (MSC) properties: an MSC banking protocol validation for the Hellenic Cord Blood Bank," *Transfusion*, vol. 54, no. 12, pp. 3108–3120, 2014.
- [39] K. Mareschi, D. Rustichelli, R. Calabrese et al., "Multipotent mesenchymal stromal stem cell expansion by plating whole bone marrow at a low cellular density: a more advantageous method for clinical use," *Stem Cells International*, vol. 2012, Article ID 920581, 10 pages, 2012.
- [40] Y.-J. Bae, Y.-R. Kwon, H. J. Kim, S. Lee, and Y.-J. Kim, "Enhanced differentiation of mesenchymal stromal cells by three-dimensional culture and azacitidine," *Blood Research*, vol. 52, no. 1, pp. 18–24, 2017.
- [41] A. Bogdanova-Jatniece, U. Berzins, and T. Kozlovskā, "Growth properties and pluripotency marker expression of spontaneously formed three-dimensional aggregates of human adipose-derived stem cells," *International Journal of Stem Cells*, vol. 7, no. 2, pp. 143–152, 2014.
- [42] Y. Petrenko, E. Syková, and Š. Kubinová, "The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids," *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 94, 2017.
- [43] C. Tan, H. Shichinohe, Z. Wang et al., "Feasibility and efficiency of human bone marrow stromal cell culture with allogeneic platelet lysate-supplementation for cell therapy against stroke," *Stem Cells International*, vol. 2016, Article ID 6104780, 11 pages, 2016.
- [44] P. Wuchter, M. Vetter, R. Saffrich et al., "Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells," *Experimental Hematology*, vol. 44, no. 6, pp. 508–518, 2016.
- [45] L. Vanda S, A. Ngo, and H. Tzu Ni, "A xeno-free, serum-free expansion medium for ex-vivo expansion and maintenance of major human tissue-derived mesenchymal stromal cells," *Translational Biomedicine*, vol. 9, no. 02, 2018.

- [46] M. Cimino, R. M. Gonçalves, C. C. Barrias, and M. C. L. Martins, "Xeno-free strategies for safe human mesenchymal stem/stromal cell expansion: supplements and coatings," *Stem Cells International*, vol. 2017, Article ID 6597815, 13 pages, 2017.
- [47] J. R. Smith, K. Pfeifer, F. Petry, N. Powell, J. Delzeit, and M. L. Weiss, "Standardizing umbilical cord mesenchymal stromal cells for translation to clinical use: selection of GMP-compliant medium and a simplified isolation method," *Stem Cells International*, vol. 2016, Article ID 6810980, 14 pages, 2016.
- [48] D. Hisamatsu, M. Ohno-Oishi, S. Nakamura, Y. Mabuchi, and H. Naka-Kaneda, "Growth differentiation factor 6 derived from mesenchymal stem/stromal cells reduces age-related functional deterioration in multiple tissues," *Aging*, vol. 8, no. 6, pp. 1259–1275, 2016.
- [49] M. Tobita, S. Tajima, and H. Mizuno, "Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma: stem cell transplantation methods that enhance stemness," *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 215, 2015.
- [50] E. Y. Kim, K.-B. Lee, J. Yu et al., "Neuronal cell differentiation of mesenchymal stem cells originating from canine amniotic fluid," *Human Cell*, vol. 27, no. 2, pp. 51–58, 2014.
- [51] D. Legzdina, A. Romanauska, S. Nikulshin, T. Kozlovskaya, and U. Berzins, "Characterization of senescence of culture-expanded human adipose-derived mesenchymal stem cells," *International Journal of Stem Cells*, vol. 9, no. 1, pp. 124–136, 2016.
- [52] M. Matjusaitis, G. Chin, E. A. Sarnoski, and A. Stolzing, "Biomarkers to identify and isolate senescent cells," *Ageing Research Reviews*, vol. 29, pp. 1–12, 2016.
- [53] M. Breitbach, T. Bostani, W. Roell et al., "Potential risks of bone marrow cell transplantation into infarcted hearts," *Blood*, vol. 110, no. 4, pp. 1362–1369, 2007.
- [54] X. Liu, J. Qin, Q. Luo et al., "Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells," *Journal of Cellular and Molecular Medicine*, vol. 17, pp. 1160–1172, 2013.
- [55] E. K. Muioli, L. Hong, and J. J. Mao, "Inhibition of osteogenic differentiation of human mesenchymal stem cells," *Wound Repair and Regeneration*, vol. 15, no. 3, pp. 413–421, 2007.
- [56] N. Xu, H. Liu, F. Qu et al., "Hypoxia inhibits the differentiation of mesenchymal stem cells into osteoblasts by activation of Notch signaling," *Experimental and Molecular Pathology*, vol. 94, no. 1, pp. 33–39, 2013.
- [57] B. M. Abdallah and M. Kassem, "New factors controlling the balance between osteoblastogenesis and adipogenesis," *Bone*, vol. 50, no. 2, pp. 540–545, 2012.
- [58] L. V. di Bonzo, I. Ferrero, C. Cravanzola et al., "Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential," *Gut*, vol. 57, no. 2, pp. 223–231, 2008.
- [59] C. Kan, L. Chen, Y. Hu et al., "Microenvironmental factors that regulate mesenchymal stem cells: lessons learned from the study of heterotopic ossification," *Histology and Histopathology*, vol. 32, no. 10, pp. 977–985, 2017.
- [60] J. Liao, X. Chen, Y. Li et al., "Transfer of bone-marrow-derived mesenchymal stem cells influences vascular remodeling and calcification after balloon injury in hyperlipidemic rats," *Journal of Biomedicine & Biotechnology*, vol. 2012, Article ID 165296, 7 pages, 2012.
- [61] E. Ko, K. Y. Lee, and D. S. Hwang, "Human umbilical cord blood-derived mesenchymal stem cells undergo cellular senescence in response to oxidative stress," *Stem Cells and Development*, vol. 21, no. 11, pp. 1877–1886, 2012.
- [62] B. R. Stab, L. Martinez, A. Grimaldo et al., "Mitochondrial functional changes characterization in young and senescent human adipose derived MSCs," *Frontiers in Aging Neuroscience*, vol. 8, p. 299, 2016.
- [63] A.-Y. So, J.-W. Jung, S. Lee, H.-S. Kim, and K.-S. Kang, "DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs," *PLoS One*, vol. 6, no. 5, article e19503, 2011.
- [64] J. Savickienė, S. Baronaitė, A. Zentelytė, G. Treigyte, and R. Navakauskienė, "Senescence-associated molecular and epigenetic alterations in mesenchymal stem cell cultures from amniotic fluid of normal and fetus-affected pregnancy," *Stem Cells International*, vol. 2016, Article ID 2019498, 13 pages, 2016.
- [65] Z. Li, C. Liu, Z. Xie et al., "Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation," *PLoS One*, vol. 6, no. 6, article e20526, 2011.
- [66] J. P. da Costa, R. Vitorino, G. M. Silva, C. Vogel, A. C. Duarte, and T. Rocha-Santos, "A synopsis on aging-theories, mechanisms and future prospects," *Ageing Research Reviews*, vol. 29, pp. 90–112, 2016.
- [67] C. Bellotti, C. Capanni, G. Lattanzi, D. Donati, E. Lucarelli, and S. Duchi, "Detection of mesenchymal stem cells senescence by prelamin A accumulation at the nuclear level," *Springerplus*, vol. 5, no. 1, p. 1427, 2016.
- [68] J. S. Heo, H. O. Kim, S. Y. Song, D. H. Lew, Y. Choi, and S. Kim, "Poly-L-lysine prevents senescence and augments growth in culturing mesenchymal stem cells *ex vivo*," *BioMed Research International*, vol. 2016, Article ID 8196078, 13 pages, 2016.
- [69] K. O'Hagan-Wong, S. Nadeau, A. Carrier-Leclerc et al., "Increased IL-6 secretion by aged human mesenchymal stromal cells disrupts hematopoietic stem and progenitor cells' homeostasis," *Oncotarget*, vol. 7, no. 12, pp. 13285–13296, 2016.
- [70] G.-H. Di, Y. Liu, Y. Lu, J. Liu, C. Wu, and H.-F. Duan, "IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells," *PLoS One*, vol. 9, no. 11, article e113572, 2014.
- [71] H. J. Jin, H. J. Lee, J. Heo et al., "Senescence-associated MCP-1 secretion is dependent on a decline in BMI1 in human mesenchymal stromal cells," *Antioxidants & Redox Signaling*, vol. 24, no. 9, pp. 471–485, 2016.
- [72] J. Carlos Sepúlveda, M. Tomé, M. Eugenia Fernández et al., "Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model," *Stem Cells*, vol. 32, no. 7, pp. 1865–1877, 2014.
- [73] S. M. Hwang, C.-J. See, J. Choi et al., "The application of an in situ karyotyping technique for mesenchymal stromal cells: a validation and comparison study with classical G-banding," *Experimental & Molecular Medicine*, vol. 45, no. 12, article e68, 2013.
- [74] S. Y. Kim, K. Im, S. N. Park et al., "Asymmetric aneuploidy in mesenchymal stromal cells detected by in situ karyotyping and fluorescence in situ hybridization: suggestions for

- reference values for stem cells," *Stem Cells and Development*, vol. 24, no. 1, pp. 77–92, 2015.
- [75] L. Wang, Y. Yang, Y. Zhu et al., "Characterization of placenta-derived mesenchymal stem cells cultured in autologous human cord blood serum," *Molecular Medicine Reports*, vol. 6, no. 4, pp. 760–766, 2012.
- [76] M. Miura, Y. Miura, H. M. Padilla-Nash et al., "Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation," *Stem Cells*, vol. 24, no. 4, pp. 1095–1103, 2006.
- [77] J.-O. Jeong, J. W. Han, J.-M. Kim et al., "Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy," *Circulation Research*, vol. 108, no. 11, pp. 1340–1347, 2011.
- [78] M.-Y. Wang, J. Nestvold, Ø. Rekdal, G. Kvalheim, and Ø. Fodstad, "A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained *in vitro* and *in vivo* stemness properties," *Experimental Cell Research*, vol. 352, no. 2, pp. 218–224, 2017.
- [79] D. Rubio, J. Garcia-Castro, M. C. Martín et al., "Spontaneous human adult stem cell transformation," *Cancer Research*, vol. 65, no. 8, pp. 3035–3039, 2005.
- [80] R. de la Fuente, A. Bernad, J. Garcia-Castro, M. C. Martín, and J. C. Cigudosa, "Retraction: spontaneous human adult stem cell transformation," *Cancer Research*, vol. 70, no. 16, p. 6682, 2010.
- [81] V. Lo Sardo, W. Ferguson, G. A. Erikson, E. J. Topol, K. K. Baldwin, and A. Torkamani, "Influence of donor age on induced pluripotent stem cells," *Nature Biotechnology*, vol. 35, no. 1, pp. 69–74, 2016.
- [82] B. G. Stultz, K. McGinnis, E. E. Thompson, J. L. Lo Surdo, S. R. Bauer, and D. A. Hursh, "Chromosomal stability of mesenchymal stromal cells during *in vitro* culture," *Cytotherapy*, vol. 18, no. 3, pp. 336–343, 2016.
- [83] H. Polzer, E. Volkmer, M. M. Saller et al., "Long-term detection of fluorescently labeled human mesenchymal stem cell *in vitro* and *in vivo* by semi-automated microscopy," *Tissue Engineering. Part C, Methods*, vol. 18, no. 2, pp. 156–165, 2012.
- [84] I. Kassis, A. Vaknin-Dembinsky, J. Bulte, and D. Karussis, "Effects of supermagnetic iron oxide labeling on the major functional properties of human mesenchymal stem cells from multiple sclerosis patients," *International Journal of Stem Cells*, vol. 3, no. 2, pp. 144–153, 2010.
- [85] E. Akhan, D. Tuncel, and K. C. Akcali, "Nanoparticle labeling of bone marrow-derived rat mesenchymal stem cells: their use in differentiation and tracking," *BioMed Research International*, vol. 2015, Article ID 298430, 9 pages, 2015.
- [86] W.-W. Cai, L. J. Wang, S. J. Li et al., "Effective tracking of bone mesenchymal stem cells *in vivo* by magnetic resonance imaging using melanin-based gadolinium<sup>3+</sup> nanoparticles," *Journal of Biomedical Materials Research. Part A*, vol. 105, no. 1, pp. 131–137, 2017.
- [87] R. Schäfer, R. Kehlbach, M. Müller et al., "Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability," *Cytotherapy*, vol. 11, no. 1, pp. 68–78, 2009.
- [88] R. Schäfer, R. Bantleon, R. Kehlbach et al., "Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles," *BMC Cell Biology*, vol. 11, no. 1, p. 22, 2010.
- [89] S. K. Mishra, S. Khushu, and G. Gangenahalli, "Biological effects of iron oxide-protamine sulfate complex on mesenchymal stem cells and its relaxometry based labeling optimization for cellular MRI," *Experimental Cell Research*, vol. 351, no. 1, pp. 59–67, 2017.
- [90] G. Zhang, Z. Na, B. Ren, X. Zhao, and W. Liu, "Impacts of fluorescent superparamagnetic iron oxide (SPIO)-labeled materials on biological characteristics and osteogenesis of bone marrow mesenchymal stem cells (BMSCs)," *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 8, pp. 12172–12181, 2015.
- [91] E. Roeder, C. Henrionnet, J. C. Goebel et al., "Dose-response of superparamagnetic iron oxide labeling on mesenchymal stem cells chondrogenic differentiation: a multi-scale *in vitro* study," *PLoS One*, vol. 9, no. 5, article e98451, 2014.
- [92] S.-C. Hsieh, F.-F. Wang, S.-C. Hung, Y.-J. Chen, and Y.-J. Wang, "The internalized CdSe/ZnS quantum dots impair the chondrogenesis of bone marrow mesenchymal stem cells," *Journal of Biomedical Materials Research Part B: Applied Biomaterials*, vol. 79B, no. 1, pp. 95–101, 2006.
- [93] P. Nold, R. Hartmann, N. Feliu et al., "Optimizing conditions for labeling of mesenchymal stromal cells (MSCs) with gold nanoparticles: a prerequisite for *in vivo* tracking of MSCs," *Journal of Nanobiotechnology*, vol. 15, no. 1, p. 24, 2017.
- [94] C. Gallina, T. Capelòla, S. Saviozzi et al., "Human mesenchymal stem cells labelled with dye-loaded amorphous silica nanoparticles: long-term biosafety, stemness preservation and traceability in the beating heart," *Journal of Nanobiotechnology*, vol. 13, no. 1, p. 77, 2015.
- [95] F. Ji, H.-G. Duan, C.-Q. Zheng, and J. Li, "Comparison of chloromethyl-dialkylcarbocyanine and green fluorescent protein for labeling human umbilical mesenchymal stem cells," *Biotechnology Letters*, vol. 37, no. 2, pp. 437–447, 2015.
- [96] Y. Guo, L. Su, J. Wu et al., "Assessment of the green fluorescence protein labeling method for tracking implanted mesenchymal stem cells," *Cytotechnology*, vol. 64, no. 4, pp. 391–401, 2012.
- [97] M. Nagyova, L. Slovinska, J. Blasko et al., "A comparative study of PKH67, DiI, and BrdU labeling techniques for tracing rat mesenchymal stem cells," *In Vitro Cellular & Developmental Biology. Animal*, vol. 50, no. 7, pp. 656–663, 2014.
- [98] S. E. Boddington, E. J. Sutton, T. D. Henning et al., "Labeling human mesenchymal stem cells with fluorescent contrast agents: the biological impact," *Molecular Imaging and Biology*, vol. 13, no. 1, pp. 3–9, 2011.
- [99] E. Wolfs, B. Holvoet, R. Gijssbers et al., "Optimization of multimodal imaging of mesenchymal stem cells using the human sodium iodide symporter for PET and Cerenkov luminescence imaging," *PLoS One*, vol. 9, no. 4, article e94833, 2014.
- [100] E. Wolfs, T. Struys, T. Notelaers et al., "18F-FDG labeling of mesenchymal stem cells and multipotent adult progenitor cells for PET imaging: effects on ultrastructure and differentiation capacity," *Journal of Nuclear Medicine*, vol. 54, no. 3, pp. 447–454, 2013.



**Hindawi**

Submit your manuscripts at  
[www.hindawi.com](http://www.hindawi.com)

